Sead Crnalic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sead Crnalic has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anders Bergh
Biomedical Sciences (Pathology), and
3 shared publicationsAnders Widmark
Radiation Sciences (Oncology), Umeå University, Umeå, Sweden
3 shared publicationsChrister Hildingsson
3 shared publicationsRichard Löfvenberg
3 shared publications- Anders Bergh
Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
1 shared publication - Anders Widmark
Department of Radiation Sciences, Oncology, Umeå University, 901 87 Umea, Sweden
1 shared publication
Latest Publications
- 21 September 2016
- Published by Bioscientifica in Endocrine Abstracts
High levels of the AR-V7 splice variant and co-amplification of the Golgi protein coding YIPF6 in AR amplified prostate cancer bone metastases
The relation between androgen receptor (AR) gene amplification and other mechanisms behind castration-resistance in prostate cancer, such as increased expression of constitutively active AR variants and steroid-converting enzymes have been poorly examined. Specific aims of this study were to examine AR amplification in treatment-naïve and castration-resistant prostate cancer (CRPC) bone metastases and to explore molecular and functional differences. AR gene amplification was assessed and verified in 16 (53%) of the CRPC bone metastases (n=30), and in none of the untreated bone metastases (n=10). AR gene amplification was associated with increased AR mRNA levels and its constitutively active AR-V7 splice variant, as well as with co-amplification of genes in the AR proximity at Xq12, such as YIPF6. Therefore, the paper focused on evaluating functional effects of YIPF6 overexpression. Members of the Yip1 protein family are mainly localized to the ER and Golgi apparatus and are thought to be involved in vesicle transport. Here we demonstrate YIPF6 protein expression in the Golgi of PC cells, and show that overexpression leads to reduced cell proliferation and colony formation. Interestingly, high YIPF6 levels also increased production of extracellular vesicles (EVs) containing coagulation factors such as tissue factor, fibrinogen and factor XIII. While investigating the EVs in vitro an ability to stimulate blood coagulation was demonstrated, and we therefore suggest that YIPF6 amplification and overexpression in CRPC bone tumors may lead to a local and systemic stimulation of coagulation mediated by pro-coagulant EVs. Funding: Swedish Research Council, Swedish Cancer Society, Cancer Research Foundation in Northern Sweden, Lion’s Cancer Research Foundation, The county of Västerbotten, and Umeå University. Presenting Author: Erik Djusberg, Umeå universitet, Institutionen för medicinsk biovetenskap, Umeå Sweden. Email: erik.djusberg@umu.se
- 21 September 2016
- Published by Bioscientifica in Endocrine Abstracts
High levels of the AR-V7 splice variant and co-amplification of the Golgi protein coding YIPF6 in AR amplified prostate cancer bone metastases
The relation between androgen receptor (AR) gene amplification and other mechanisms behind castration-resistance in prostate cancer, such as increased expression of constitutively active AR variants and steroid-converting enzymes have been poorly examined. Specific aims of this study were to examine AR amplification in treatment-naïve and castration-resistant prostate cancer (CRPC) bone metastases and to explore molecular and functional differences. AR gene amplification was assessed and verified in 16 (53%) of the CRPC bone metastases (n=30), and in none of the untreated bone metastases (n=10). AR gene amplification was associated with increased AR mRNA levels and its constitutively active AR-V7 splice variant, as well as with co-amplification of genes in the AR proximity at Xq12, such as YIPF6. Therefore, the paper focused on evaluating functional effects of YIPF6 overexpression. Members of the Yip1 protein family are mainly localized to the ER and Golgi apparatus and are thought to be involved in vesicle transport. Here we demonstrate YIPF6 protein expression in the Golgi of PC cells, and show that overexpression leads to reduced cell proliferation and colony formation. Interestingly, high YIPF6 levels also increased production of extracellular vesicles (EVs) containing coagulation factors such as tissue factor, fibrinogen and factor XIII. While investigating the EVs in vitro an ability to stimulate blood coagulation was demonstrated, and we therefore suggest that YIPF6 amplification and overexpression in CRPC bone tumors may lead to a local and systemic stimulation of coagulation mediated by pro-coagulant EVs. Funding: Swedish Research Council, Swedish Cancer Society, Cancer Research Foundation in Northern Sweden, Lion’s Cancer Research Foundation, The county of Västerbotten, and Umeå University. Presenting Author: Erik Djusberg, Umeå universitet, Institutionen för medicinsk biovetenskap, Umeå Sweden. Email: erik.djusberg@umu.se
- 15 December 2012
- Published by Wolters Kluwer Health in Spine
- Vol. 37 (26) , 2168-2176
Predicting Survival for Surgery of Metastatic Spinal Cord Compression in Prostate Cancer
Study Design. We retrospectively analyzed prognostic factors for survival in patients with prostate cancer operated for metastatic spinal cord compression. Objective. The aim was to obtain a clinical score for prediction of survival after surgery. Summary of Background Data. Survival prognosis is important when deciding about treatment of patients with metastatic spinal cord compression. The criteria for identifying patients with prostate cancer who may benefit from surgical treatment are unclear. Methods. The study comprised 68 consecutive patients with prostate cancer operated for metastatic spinal cord compression at Umeå University Hospital, Sweden. The indication for surgery was neurological deficit; 53 patients had hormone-refractory prostate cancer and 15 patients had previously untreated, hormone-naïve prostate cancer. In 42 patients, posterior decompression was performed and 26 patients were operated with posterior decompression and stabilization. Results. A new score for prediction of survival was developed on the basis of the results of survival analyses. The score includes hormone status of prostate cancer, Karnofsky performance status, evidence of visceral metastasis, and preoperative serum prostate-specific antigen (PSA). The total scores ranged from 0 to 6. Three prognostic groups were formulated: group A (n = 32) with scores 0–1; group B (n = 23) with scores 2–4, and group C (n = 12) with scores 5–6. The median overall survival was 3 (0.3–20) months in group A, 16 (1.8–59) months in group B, and more than half (7 of 12) of patients were still alive in group C. Conclusion. We present a new prognostic score for predicting survival of patients with prostate cancer after surgery for metastatic spinal cord compression. The score is easy to apply in clinical practice and may be used as additional support when making decision about treatment.
- 15 December 2012
- Published by Wolters Kluwer Health in Spine
- Vol. 37 (26) , 2168-2176
Predicting Survival for Surgery of Metastatic Spinal Cord Compression in Prostate Cancer
Study Design. We retrospectively analyzed prognostic factors for survival in patients with prostate cancer operated for metastatic spinal cord compression. Objective. The aim was to obtain a clinical score for prediction of survival after surgery. Summary of Background Data. Survival prognosis is important when deciding about treatment of patients with metastatic spinal cord compression. The criteria for identifying patients with prostate cancer who may benefit from surgical treatment are unclear. Methods. The study comprised 68 consecutive patients with prostate cancer operated for metastatic spinal cord compression at Umeå University Hospital, Sweden. The indication for surgery was neurological deficit; 53 patients had hormone-refractory prostate cancer and 15 patients had previously untreated, hormone-naïve prostate cancer. In 42 patients, posterior decompression was performed and 26 patients were operated with posterior decompression and stabilization. Results. A new score for prediction of survival was developed on the basis of the results of survival analyses. The score includes hormone status of prostate cancer, Karnofsky performance status, evidence of visceral metastasis, and preoperative serum prostate-specific antigen (PSA). The total scores ranged from 0 to 6. Three prognostic groups were formulated: group A (n = 32) with scores 0–1; group B (n = 23) with scores 2–4, and group C (n = 12) with scores 5–6. The median overall survival was 3 (0.3–20) months in group A, 16 (1.8–59) months in group B, and more than half (7 of 12) of patients were still alive in group C. Conclusion. We present a new prognostic score for predicting survival of patients with prostate cancer after surgery for metastatic spinal cord compression. The score is easy to apply in clinical practice and may be used as additional support when making decision about treatment.
- 3 September 2012
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 52 (4) , 809-815
Early diagnosis and treatment is crucial for neurological recovery after surgery for metastatic spinal cord compression in prostate cancer
Background. Spinal cord compression is an oncological and surgical emergency. Delays in referral and diagnosis may influence functional outcome. It is therefore important to identify patients who will regain or maintain the ability to walk after surgery. The aim of the present study was to examine current practice for referral and diagnosis of prostate cancer patients with spinal cord compression and to identify prognostic factors for neurological outcome after surgery. Patients and methods. The study includes 68 consecutive patients with prostate cancer who underwent surgery due to neurological compromise. Intervals from onset of neurological symptoms to referral, diagnosis, and treatment were analyzed in relation to functional outcome. The prognostic significance of preoperative clinical parameters on gait function one month after surgery was evaluated. Results. Patients who were referred from local hospitals had longer delay to surgery than those who directly presented to the cancer center (p = 0.004). The rate of diagnosis with MRI increased through the week and peaked on Friday, with few patients being diagnosed during weekends. The ability to walk before surgery, hormone-naive prostate cancer, and/or shorter time from loss of ambulation were associated with more favorable neurological outcome. In patients with hormone-refractory disease who were unable to walk before surgery regaining ambulation was associated with: duration of paresis < 48 hours (p = 0.005), good preoperative performance status (p = 0.04), preoperative PSA serum level < 200 ng/ml (p = 0.03), and surgery with posterior decompression and stabilization (p = 0.03). Conclusion. Early diagnosis and rapid treatment of spinal cord compression in prostate cancer patients is crucial for neurological recovery. Raising awareness of the condition among patients at risk and among physicians is of outmost importance as well as improving local and regional guidelines for treatment.
- 3 September 2012
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 52 (4) , 809-815
Early diagnosis and treatment is crucial for neurological recovery after surgery for metastatic spinal cord compression in prostate cancer
Background. Spinal cord compression is an oncological and surgical emergency. Delays in referral and diagnosis may influence functional outcome. It is therefore important to identify patients who will regain or maintain the ability to walk after surgery. The aim of the present study was to examine current practice for referral and diagnosis of prostate cancer patients with spinal cord compression and to identify prognostic factors for neurological outcome after surgery. Patients and methods. The study includes 68 consecutive patients with prostate cancer who underwent surgery due to neurological compromise. Intervals from onset of neurological symptoms to referral, diagnosis, and treatment were analyzed in relation to functional outcome. The prognostic significance of preoperative clinical parameters on gait function one month after surgery was evaluated. Results. Patients who were referred from local hospitals had longer delay to surgery than those who directly presented to the cancer center (p = 0.004). The rate of diagnosis with MRI increased through the week and peaked on Friday, with few patients being diagnosed during weekends. The ability to walk before surgery, hormone-naive prostate cancer, and/or shorter time from loss of ambulation were associated with more favorable neurological outcome. In patients with hormone-refractory disease who were unable to walk before surgery regaining ambulation was associated with: duration of paresis < 48 hours (p = 0.005), good preoperative performance status (p = 0.04), preoperative PSA serum level < 200 ng/ml (p = 0.03), and surgery with posterior decompression and stabilization (p = 0.03). Conclusion. Early diagnosis and rapid treatment of spinal cord compression in prostate cancer patients is crucial for neurological recovery. Raising awareness of the condition among patients at risk and among physicians is of outmost importance as well as improving local and regional guidelines for treatment.
- Open Access
- 10 June 2011
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 83 (1) , 80-86
Outcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer
The criteria for selecting patients who may benefit from surgery of spinal cord compression in metastatic prostate cancer are poorly defined. We therefore studied patients operated for metastatic spinal cord compression in order to evaluate outcome of surgery and to find predictors of survival. We reviewed the records of 54 consecutive patients with metastatic prostate cancer who were operated for spinal cord compression at Umeå University Hospital. The indication for surgery was neurological deficit due to spinal cord compression. 41 patients had hormone-refractory cancer and 13 patients had previously untreated, hormone-naïve prostate cancer. 29 patients were operated with posterior decompression only, and in 25 patients posterior decompression and stabilization was performed. Preoperatively, 6/54 of patients were able to walk. 1 month after surgery, 33 patients were walking, 15 were non-ambulatory, and 6 had died. Mortality rate was 11% at 1 month, 41% at 6 months, and 59% at 1 year. In the hormone-naïve group, 8/13 patients were still alive with a median postoperative follow-up of 26 months. In the hormone-refractory group, median survival was 5 months. Patients with hormone-refractory disease and Karnofsky performance status (KPS) of ≤ 60% had median survival of 2.5 months, whereas those with KPS of 70% and KPS of ≥ 80% had a median survival of 7 months and 18 months, respectively (p < 0.001). Visceral metastases were present in 12/41 patients with hormone-refractory tumor at the time of spinal surgery, and their median survival was 4 months-as compared to 10 months in patients without visceral metastases (p = 0.003). Complications within 30 days of surgery occurred in 19/54 patients. Our results indicate that patients with hormone-naive disease, and those with hormone-refractory disease with good performance status and lacking visceral metastases, may be helped by surgery for metastatic spinal cord compression.
- 10 June 2011
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 83 (1) , 80-86
Open AccessOutcome after surgery for metastatic spinal cord compression in 54 patients with prostate cancer
The criteria for selecting patients who may benefit from surgery of spinal cord compression in metastatic prostate cancer are poorly defined. We therefore studied patients operated for metastatic spinal cord compression in order to evaluate outcome of surgery and to find predictors of survival. We reviewed the records of 54 consecutive patients with metastatic prostate cancer who were operated for spinal cord compression at Umeå University Hospital. The indication for surgery was neurological deficit due to spinal cord compression. 41 patients had hormone-refractory cancer and 13 patients had previously untreated, hormone-naïve prostate cancer. 29 patients were operated with posterior decompression only, and in 25 patients posterior decompression and stabilization was performed. Preoperatively, 6/54 of patients were able to walk. 1 month after surgery, 33 patients were walking, 15 were non-ambulatory, and 6 had died. Mortality rate was 11% at 1 month, 41% at 6 months, and 59% at 1 year. In the hormone-naïve group, 8/13 patients were still alive with a median postoperative follow-up of 26 months. In the hormone-refractory group, median survival was 5 months. Patients with hormone-refractory disease and Karnofsky performance status (KPS) of ≤ 60% had median survival of 2.5 months, whereas those with KPS of 70% and KPS of ≥ 80% had a median survival of 7 months and 18 months, respectively (p < 0.001). Visceral metastases were present in 12/41 patients with hormone-refractory tumor at the time of spinal surgery, and their median survival was 4 months-as compared to 10 months in patients without visceral metastases (p = 0.003). Complications within 30 days of surgery occurred in 19/54 patients. Our results indicate that patients with hormone-naive disease, and those with hormone-refractory disease with good performance status and lacking visceral metastases, may be helped by surgery for metastatic spinal cord compression.